David Berry joined Flagship Pioneering in 2005 where he is a General Partner, focusing on conceiving, creating, resourcing, and launching groundbreaking companies. David has co-founded more than 20 companies across life sciences, technology and sustainability, including Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), Indigo Agriculture, Evelo Biosciences, Eleven Biotherapeutics (NASDAQ: EBIO), LS9 (acquired by Renewable Energy Group), Axcella Health, and Inari Agriculture. He has served as founding CEO of over 10 companies including Seres, Evelo, and Axcella, and founding Chairman of Indigo and Inari.
David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications. David and his companies have been awarded with more than 150 additional awards and honors.
David currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member. Through the UN SDSN, he has been involved with the development and implementation of the Sustainable Development Goals (SDGs)—17 goals and 169 targets that serve as the Post-2016 Development Agenda for the United Nations, as agreed upon by 193 countries. David previously served as a member of the Corporation of MIT and the Board of the Boston Philharmonic Orchestra and is currently a Board Member of the Hackley School.
David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering, through the Health Sciences and Technology program completing the fastest dual degree in the modern history of the program, during which he was awarded the Lemelson-MIT Prize award for the most inventive and innovative student at MIT.